Ashland Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.89%.
Did ASH Beat Earnings? Q4 2025 Results
Ashland delivered a disappointing close to fiscal 2025, with fourth-quarter results missing on both the top and bottom lines as persistent market headwinds and deliberate portfolio reshaping weighed on performance. Adjusted diluted EPS came in at $1.08, falling short of the $1.30 consensus estimate by 16.92%, while revenue of $478.00 million declined 8.4% year-over-year and landed just below the $479.36 million expectation. The primary culprit was Ashland's own Portfolio Optimization program, which stripped roughly $38.00 million from sales through divestitures of the Nutraceuticals and Avoca businesses and product line rationalizations; excluding those actions, organic sales fell only one percent. Adjusted EBITDA of $119.00 million represented a 25% margin, though Life Sciences and Personal Care offered brighter spots, with the former exceeding 30% Adjusted EBITDA margin for the first time. Looking ahead, Ashland guided fiscal 2026 sales of $1.83 billion to $1.91 billion and Adjusted EBITDA of $400.00 million to $430.00 million, targeting double-digit-plus adjusted EPS growth as restructuring savings and innovation initiatives begin to take hold.
- Portfolio Optimization initiatives reduced sales by approximately $38 million but improved margin profile
- Restructuring savings of approximately $30 million realized in fiscal 2025
- Improved product mix and lower SARD expenses drove Adjusted EBITDA growth ex-Portfolio Optimization
- Share repurchase activity reduced diluted shares from 49 million to 46 million year-over-year
- Personal Care delivered 5% organic sales growth with double-digit growth in globalize business lines
- Life Sciences pharma demand resilient with low-single-digit sales growth year-over-year
- Foreign currency movements contributed favorable $8 million to sales
“Ashland's fourth-quarter performance reflects our disciplined approach and ability to deliver results in line with expectations, even as market conditions remained challenging. We maintained strong margins and delivered revenue and EBITDA consistent with prior guidance. Our continued focus on execution helped offset pockets of competitive pressure and muted demand.”
Ashland CEO, on the earnings call
Forward Guidance & Outlook
For fiscal 2026, Ashland guided sales of $1,835 million to $1,905 million, reflecting organic growth of approximately one to five percent. Adjusted EBITDA is expected at $400 million to $430 million. The company targets double-digit-plus adjusted diluted EPS excluding intangibles amortization expense growth, and approximately 50 percent Ongoing Free Cash Flow conversion of Adjusted EBITDA with capital expenditures of approximately $100 million. Key assumptions include resilient Life Sciences and Personal Care end-markets, continued challenges in coatings and Intermediates, and tariff-related uncertainty. The company plans approximately $30 million in cost savings under its $90 million program, $20 million in incremental globalize sales, and $15 million in incremental innovation-driven sales. Manufacturing network optimization incremental savings are now expected at $50-55 million until China volumes recover, with the full $60 million achievable as conditions improve. Headwinds include approximately $20 million in higher compensation accruals, approximately $10 million Calvert City production unit impact, and $4 million in incremental R&D investments.
ASH YoY Financials
ASH Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.